This study is a randomized controlled trial designed to compare the effects of virtual reality-based physical therapy and conventional physical therapy on balance, gait, and fall risk in individuals with Parkinson's disease. The trial will be conducted at Shadman Medical Centre and will follow a parallel-group design. The total duration of the study will be approximately nine months following approval of the research synopsis, which will include participant recruitment, intervention delivery, follow-up assessments, and data analysis.
A total of 62 participants will be enrolled, accounting for an anticipated attrition rate of 20%. The sample size was calculated to detect clinically meaningful differences between groups with 80% statistical power at a 95% confidence level. Participants will be adults aged 45-65 years with a confirmed diagnosis of Parkinson's disease and sufficient cognitive capacity to understand instructions and participate safely in the intervention. Both male and female participants will be included. Individuals with other neurological disorders, recent musculoskeletal trauma or surgery affecting mobility or balance, or conditions that significantly impair safe participation will not be enrolled.
Participants will be recruited using a convenience sampling method and will undergo baseline assessment prior to group allocation. Randomization will be carried out using a lottery method, with allocation occurring after baseline measurements. Outcome assessors and data analysts will remain blinded to group assignment in order to minimize assessment and analysis bias.
Participants will be allocated to either conventional physical therapy or virtual reality-based physical therapy. All interventions will be delivered by licensed physiotherapists who are trained in the standardized study protocol. Both groups will receive three treatment sessions per week for eight weeks, resulting in a total of 24 sessions. Each session will last approximately 45 minutes, including warm-up and cool-down periods. Exercise intensity will be maintained at a moderate level and monitored using the Borg CR10 scale. Participants will continue their stable anti-parkinsonian medication regimen throughout the study period.
Standard safety measures will be implemented for all participants, including pre-session screening of vital signs, continuous therapist supervision, fall-risk monitoring, and use of gait belts when required. Attendance will be documented for each session, and adherence to the intervention will be defined as completion of at least 80% of the prescribed sessions.
Conventional physical therapy will focus on improving balance, gait, strength, and functional mobility through structured exercise sessions. The intervention will include balance training targeting anticipatory, reactive, and sensory integration strategies, gait training with cueing techniques, strengthening of lower-limb and core musculature, and stretching exercises during the cool-down phase. Exercise difficulty and progression will be individualized based on participant performance and tolerance.
Virtual reality-based physical therapy will involve interactive balance and gait training using immersive or semi-immersive virtual environments. Participants will engage in task-oriented activities such as weight shifting, stepping to visual targets, dynamic balance challenges, and gait-related tasks enhanced by real-time visual and auditory feedback. Reactive balance training and dual-task components may be incorporated to simulate functional and environmental demands. Task difficulty will be progressively adjusted according to performance-based criteria, with therapist supervision to ensure safety.
Outcome assessments will be conducted at baseline, mid-intervention, and post-intervention using standardized and validated clinical assessment tools administered by trained assessors in a controlled clinical environment. Assessment procedures will be standardized across all time points to ensure consistency and reliability of measurements.
Ethical approval for the study has been obtained from the Institutional Review Board of the University of Lahore. Written informed consent will be obtained from all participants prior to enrollment. Participant confidentiality will be strictly maintained through anonymization and secure handling of data. Participation will be voluntary, and participants may withdraw from the study at any time without penalty or effect on their standard medical care. All potential risks and benefits will be explained in advance, and participant safety will remain a priority throughout the study.
